SRPT Q2 2024 Earnings — Sarepta Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

SRPTSarepta Therapeutics, Inc.

$2B

Q2 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$363M+38.9% YoY

Gross Profit

$318M87.7% margin

Operating Income

-$701,000-0.2% margin

Net Income

$6M1.8% margin

EPS (Diluted)

$0.07

QoQ Revenue Growth

-12.2%

Cash Flow

Operating Cash Flow

$15M

Free Cash Flow

-$14M

Stock-Based Comp.

$50M

Balance Sheet

Total Assets

$3.4B

Total Liabilities

$2.3B

Stockholders' Equity

$1.1B

Cash & Equivalents

$384M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$363M	$261M	+38.9%
Gross Profit	$318M	$227M	+40.2%
Operating Income	-$701,000	-$134M	+99.5%
Net Income	$6M	-$24M	+127.0%

Geographic Segments

UNITED STATES

$204M86%

Rest of World

$35M14%